 Dennis W. Choi, M.D., Ph.D., graduated from Harvard College in 1974, and received the MD and PhD degrees in 1978 (the latter in Pharmacology) from Harvard University and the Harvard-MIT Program in Health Sciences and Technology. After completing residency and fellowship training in neurology at Harvard, he joined the faculty at Stanford University and began research into the mechanisms underlying pathological neuronal death. In 1991 he joined Washington University Medical School as head of the Neurology Department; there he also established the Center for the Study of Nervous System Injury, and directed the McDonnell Center for Cellular and Molecular Neurobiology. From 2001 until 2006 he was Executive Vice-President for Neuroscience at Merck Research Labs. Dr. Choi is currently Executive Director of Emory¹s strategic neurosciences initiative and Director of the Comprehensive Neuroscience Center in the Woodruff Health Sciences Center at Emory University.
He is a fellow of the American Association for the Advancement of Science, and a member of the Institute of Medicine, the Executive Committee of the Dana Alliance for Brain Research, and the College of Physicians of Philadelphia. He has served as President of the Society for Neuroscience, Vice-President of the American Neurological Association, and chairman of the U.S./Canada Regional Committee of the International Brain Research Organization. He has also served on the National Academy of Sciences’ Board on Life Sciences, and Councils for the National Institute of Neurological Disorders and Stroke, the Society for Neuroscience, the Winter Conference for Brain Research, the International Society for Cerebral Blood Flow and Metabolism, and the Neurotrauma Society. He has been a member of advisory boards for the Christopher Reeve Paralysis Foundation, the Grass Foundation, the Hereditary Disease Foundation, the Spinal Muscular Atrophy Foundation, the Harvard-MIT Program in Health Sciences and Technology, the Queen's Neuroscience Institute in Honolulu, the Max-Planck Institute in Heidelberg, the Korea Institute for Advanced Study (KIAS) in Seoul, and the US Food and Drug Administration, as well as for several university-based research consortia, biotechnology companies, and pharmaceutical companies.
|